Your browser is no longer supported. Please, upgrade your browser.
NVS Novartis AG daily Stock Chart
Novartis AG
Index- P/E29.47 EPS (ttm)2.77 Insider Own9.30% Shs Outstand2.64B Perf Week2.70%
Market Cap214.74B Forward P/E16.20 EPS next Y5.03 Insider Trans0.24% Shs Float2.53B Perf Month1.47%
Income6.67B PEG4.78 EPS next Q1.19 Inst Own10.10% Short Float0.15% Perf Quarter5.68%
Sales49.78B P/S4.31 EPS this Y-33.30% Inst Trans-1.17% Short Ratio2.70 Perf Half Y11.42%
Book/sh30.43 P/B2.68 EPS next Y6.59% ROA5.10% Target Price94.80 Perf Year-7.78%
Cash/sh- P/C- EPS next 5Y6.16% ROE9.10% 52W Range68.87 - 91.54 Perf YTD-1.61%
Dividend2.72 P/FCF108.29 EPS past 5Y-7.50% ROI7.80% 52W High-10.99% Beta0.57
Dividend %3.34% Quick Ratio0.60 Sales past 5Y-0.50% Gross Margin65.00% 52W Low18.32% ATR1.03
Employees118000 Current Ratio0.90 Sales Q/Q-1.70% Oper. Margin16.90% RSI (14)55.27 Volatility0.73% 1.02%
OptionableYes Debt/Eq0.36 EPS Q/Q-0.80% Profit Margin13.60% Rel Volume0.75 Prev Close82.03
ShortableYes LT Debt/Eq0.22 EarningsOct 25 BMO Payout95.20% Avg Volume1.36M Price81.48
Recom2.30 SMA202.11% SMA500.20% SMA2004.55% Volume1,026,044 Change-0.67%
Sep-20-16Initiated Chardan Capital Markets Buy $95
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Apr-08-08Downgrade Bear Stearns Outperform → Peer Perform
Feb-29-08Initiated Cowen & Co Neutral
Feb-29-08Downgrade HSBC Securities Neutral → Underweight
Sep-23-16 05:25PM  Tevas Valuation Multiples Compared to Other Generic Drug Players
01:09PM  Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions PR Newswire
10:01AM  Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study
07:29AM  UPDATE 1-Novartis's Zykadia gets positive results, faces Roche pressure Reuters
Sep-22-16 04:35PM  Gilead, Allergan Seen Trailing Intercept In Ongoing NASH Battle
02:00PM  A Double Dose of Trouble at Novartis
01:05PM  Does Novartis AG (NVS) Have The Solution For Malaria? at Insider Monkey
Sep-20-16 11:04AM  Teva, Eli Lilly Have Migraine Treatments in Trial Phases
10:46AM  Breaking the mould: GSK picks Big Pharma's first female CEO
10:15AM  Novartis A Buy At Chardan
10:05AM  Alder BioPharmaceuticalss Migraine Therapy Shows Promise
08:05AM  Entering Migraine Market Wont Be Easy for Novartis, Amgen
06:50AM  Pfizer (PFE) Breast Cancer Drug Ibrance Wins CHMP Backing
05:52AM  Coverage initiated on Novartis AG by Chardan Capital Markets
Sep-19-16 10:16AM  Novartis (NVS) Presents Positive Data on Cardiovascular Drug
Sep-17-16 11:41AM  Is This New Market the Biggest Investment Idea of the Decade? at Motley Fool
11:00AM  Novartis says MS drug cut risk of disability advance in study Reuters
05:00AM  Novartis Drug for Multiple Sclerosis Shows Reduction in Risks at Bloomberg
Sep-16-16 12:09PM  Novartis says experimental drug helps chronic migraine sufferers
09:21AM  Novartis Reports Positive Phase II Data on Migraine Drug
06:00AM  An Attractive European Stock ETF at Morningstar
Sep-14-16 07:00AM  Our Ultimate Stock-Pickers Top 10 Dividend-Yielding Stocks at Morningstar
Sep-13-16 01:36PM  Xencor (XNCR) Doses First Patient in Myeloid Leukemia Trial
11:04AM  GSK Optimistic about Future of Its Consumer Healthcare Segment
10:25AM  Jefferies Issues Top Pharma and Biohealth Stocks to Buy at 24/7 Wall St.
10:04AM  GlaxoSmithKline Giving a Shot to Its Vaccines Business
08:04AM  Performance of GSKs Global Pharmaceuticals Franchises Mixed
Sep-12-16 04:36PM  This Firm Wins Battle Against Glaucoma By Putting A Stick In Your Eye
10:04AM  How Can Pfizer Revive Its Essential Health Business?
10:04AM  Whats the Problem with GSKs Pharmaceutical Segment?
09:54AM  The Only Thing More Extraordinary Than GlaxoSmithKline's Growth Strategy Is That It's Working at Motley Fool
08:05AM  Of GSKs Business Segments, This One Is the Sales Laggard
Sep-11-16 05:09PM  Reads For The Weed-Kend: Marijuana Roadside Testing, Pregnancy And Depression
11:53AM  This Could Save Medicare at Least $16 Billion a Year, but the Agency Is Barred From Doing It at Motley Fool
Sep-09-16 01:11PM  Will These Cancer Therapies Pay Off? (KITE, JUNO) at Investopedia
10:24AM  3 Reasons bluebird bio, Inc. Stock Dipped 13.7% in August at Motley Fool
Sep-07-16 05:44PM  Europe: New safe haven?
05:24PM  GW Pharmaceuticals Stock Pops On Report Of Buyout Interest
09:17AM  Post Earnings Coverage as Cooper Cos Earnings Grows 97 Percent
Sep-06-16 12:23PM  Gretchen Carlson's $20 Million And Some Of The Biggest Sexual Harassment Payouts Ever
10:26AM  Out With The Old, In With The New: State Agencies Seem To Prefer Marijuana Over Opioids
09:38AM  Novartis (NVS) Reports Positive Data on Ultibro Breezhaler
Sep-05-16 08:04AM  Incytes Product Portfolio Includes Potentially Lucrative Drugs
Sep-04-16 02:05PM  How Google Plans to Reinvent Healthcare at Motley Fool
Sep-02-16 04:12PM  3 Biotech Stocks That Could Make Big Moves In September
04:04PM  Understanding Incytes Revenue Stream in 2Q16
02:04PM  Is Incyte Hurt by Having Only One FDA-Approved Drug?
10:04AM  PFE to Enjoy Being Sole Provider of Key Breast Cancer Treatment
09:17AM  Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar
Sep-01-16 11:10AM  [$$] Novartis Carts Itself Off at
09:17AM  Blog Coverage FDA Approves Novartis Erelzi as Biosimilar to Amgens Enbrel
09:02AM  Novartis Rings Another Cell-Therapy Alarm Bell at Bloomberg
08:04AM  How Analysts See United Therapeutics Continued Performance
Aug-31-16 06:14PM  Merck Will Hold Steady on Div Increase Despite Flat Revenue Growth
04:43PM  Novartis Closing Cell Therapy Unit; CAR-T Stocks Tumble
02:39PM  Juno and Kite hit today
02:34PM  Future of immunotherapy
01:32PM  Novartis Disbands Cell Therapy Unit; What's Ahead For Kite, Juno? at
12:00PM  Novartis Dissolves Its Cell Therapy Unit, Cutting 120 Positions at Bloomberg
10:05AM  Why Pfizer Is Trading at a Discount on an Earnings Basis
09:17AM  BTIG Is 'Generally Skeptical' On Kite Pharma Expectations
08:59AM  Novartis (NVS) Gets FDA Nod for Biosimilar Version of Enbrel
08:32AM  Novartis Dissolves CAR-T Unit, Cutting 120 Positions at Forbes
12:00AM  Struggling Vaccines From Novartis Turn Into Sales Boon for Glaxo at Bloomberg
Aug-30-16 06:29PM  Novartis wins US OK for biosimilar version of Amgen's Enbrel
04:40PM  U.S. FDA approves Novartis biosimilar to Amgen's Enbrel Reuters
04:04PM  Generic Competition Not a Threat to UTHRs Remodulin
Aug-29-16 01:41PM  Heres Whats Important With The Novartis AG (ADR) (NVS) MS Data at Insider Monkey
01:30PM  Almost The Whole World In This ETF's Hands
Aug-26-16 06:18PM  Can Novartis Tide Over the Alcon Crisis?
04:03PM  Novartis AG (NVS) Announces Positive Phase III Results For MS Drug at Insider Monkey
10:20AM  Novartis (NVS) Reports Positive Phase III Results on MS Drug
Aug-25-16 11:04AM  AbbVie Expects to Launch Zinbryta in the US in August
Aug-24-16 04:49PM  Why Momenta Pharmaceuticals Shares Made a Late-Day Jump Higher at Motley Fool
03:30PM  Waiting For Growth, Or A Better Valuation, Argus Stays Sidelined On Novartis Shares
11:04AM  Imbruvica Continues to Report Better-than-Expected Sales in 2016
08:50AM  Novartis Licenses Anti-PCSK9 Antibody to Cyon Therapeutics
Aug-23-16 07:04PM  Performance of AstraZenecas Growth Platforms in 2Q16
05:04PM  Why AstraZeneca Reported Negative Growth in 2Q16
11:11AM  Top 6 Pharmaceutical Companies Globally at Investopedia
11:00AM  Cyon Therapeutics Inc. acquires world-wide rights to an anti-PCSK9 antibody for use in Severe Infection and Sepsis CNW Group
Aug-22-16 11:04AM  How Merial Contributes to Sanofis Growth
Aug-21-16 11:41AM  3 Reasons Medivation Is the Juiciest Target in Biotech at Motley Fool
Aug-19-16 01:19PM  Novartis: First-Class Pharmaceuticals
11:04AM  What Happened to Sanofis Consumer Healthcare and Generics Franchise in 2Q16?
Aug-18-16 01:30PM  5 Stocks That Beat The Market In A Crash
09:06AM  Genzyme Continued to Boost Growth for Sanofi in 2Q16
09:04AM  Ozanimod May Prove to Be a Strong Growth Driver for Celgene
Aug-17-16 11:04AM  CELGs Otezla Continues Dominating US Inflammation and Immunology
08:21AM  Better Buy: Amgen Inc. vs. Biogen at Motley Fool
08:13AM  With new president and focus on big investors, Cellceutix aims for the Nasdaq at
02:54AM  CSL to hike spending after profit fall AAP
Aug-16-16 09:23PM  CSL to raise $US500m after mixed results AAP
06:48PM  Novartis Needs to Stem the Bleeding From Gleevec Decline
09:05AM  Valeant: Are the Salix and Dermatology Portfolios Recovering?
Aug-15-16 09:13AM  Allergan to Buy ForSight VISION5, Boost Glaucoma Pipeline
Aug-13-16 06:22AM  Novartis Korea executives charged with bribing doctors
12:01AM  [$$] 5 Safe European Stocks With Yields Up to 5% at
Aug-12-16 10:00AM  Who Is Driving Novarti's Management Team? (NVS, BAYRY) at Investopedia
Aug-11-16 11:04AM  Pfizers Products with Decreasing Revenues
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines, and cell and gene therapies. The Alcon segment provides eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. The Sandoz segment offers generic prescription medicines that include active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The company has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and with Caribou Biosciences for the development of drug discovery tools. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Institutes for BioMed10% OwnerMay 11Buy18.00277,7774,999,9865,573,658May 11 06:57 PM
Novartis Bioventures Ltd10% OwnerApr 12Buy10.00300,0003,000,0002,310,924Apr 12 05:09 PM
Novartis Bioventures Ltd10% OwnerFeb 17Buy8.00375,0003,000,0001,873,791Feb 17 06:47 PM